uBriGene Launches uVivo Lentiviral Vector Platform to Accelerate Next-Generation In Vivo CAR-T Therapies
核心洞察
uBriGene Biosciences (搜索) announced the launch of its patented uVivo Lentiviral Vector (LVV) Platform, a targeted in vivo CAR-T technology enabling safer, more efficient, and commercially scalable therapies.
The platform uses a dual-engineering strategy combining a detargeted uVivo-CocalG envelope with a CD7 (搜索) nanobody to achieve precise T-cell targeting.
Combined with the LVV Turbo manufacturing process, the platform can produce thousands of CAR-T doses from a single 10 L batch, addressing lengthy timelines and high costs of conventional autologous CAR-T manufacturing.
uBriGene Biosciences (搜索), a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, announced the launch of its patented uVivo Lentiviral Vector (LVV) Platform. The uVivo LVV is described as a proven and targeted in vivo CAR-T platform that enables safer, more efficient, and commercially scalable in vivo CAR-T therapies.
CAR-T cell therapy has transformed the treatment landscape for hematologic malignancies (搜索). However, conventional autologous CAR-T manufacturing requires complex ex vivo cell collection, genetic modification, expansion, and immunodepletion, resulting in lengthy manufacturing timelines and high treatment costs. To address these challenges, uBriGene developed the proprietary uVivo LVV Platform, an in vivo CAR-T technology that enables precise delivery of CAR payloads to T cells, allowing rapid generation of CAR-T cells in vivo.
"The promise of in vivo CAR-T lies in its ability to make transformative cell therapies simpler, faster, and more accessible," said Dr. Xiulian Sun, CTO and cofounder of uBriGene Biosciences (搜索). "Our uVivo LVV Platform combines proprietary and proven LVV engineering for precise T-cell targeting with an industry-leading manufacturing platform capable of producing thousands of doses from a single 10 L batch. By delivering both scientific innovation and manufacturing efficiency, we are helping pave the way toward safer, more affordable, and commercially viable in vivo CAR-T therapies."
Dual-Engineering Strategy for Precise T-Cell Targeting
The uVivo LVV Platform employs a dual-engineering strategy based on detargeting and retargeting. The platform incorporates the engineered uVivo-CocalG envelope, which has been detargeted to eliminate broad cellular tropism. Targeted delivery to T cells is achieved through a CD7 (搜索) nanobody with an optimized membrane anchoring sequence.
Manufacturing Efficiency and Scalability
By combining the uVivo LVV Platform with uBriGene's high-productivity LVV Turbo manufacturing process, the platform can produce thousands of CAR-T doses from a single 10 L manufacturing batch. Several engineering optimizations contribute to this productivity, including a sequence-optimized uVivo-CocalG delivering a 3× higher productivity increase, an optimized Ubri-CD7 (搜索) T-cell binder whose engineered transmembrane domain achieves up to a 10-fold increase in productivity, and GOI sequence optimization providing a 5× increase. These advances integrate with the LVV Turbo manufacturing platform, which features a high-yield suspension cell line and a closed downstream process for scalable production.
About uBriGene Biosciences
Founded in 2015, uBriGene Biosciences (搜索) is a leading CDMO specializing in advanced therapy medicinal products (ATMPs). The company provides integrated CDMO and CRO services for cell therapies, viral vectors, and RNA-related products, supported by in-house QC testing and regulatory IND filing. uBriGene's global GMP Centers of Excellence and proprietary platforms, including AAV-Turbo, LVV Turbo, Cell Product manufacturing, and iPSC reprogramming technologies, enable biotech and pharmaceutical companies to accelerate the development of next-generation therapies.